A Study to Assess Long-term Safety of Fezolinetant Given to Japanese Women Going Through Menopause

Hot Flashes Clinical Trial

— Starlight 3  

Official title:

A Phase 3, Randomized, Placebo-controlled, Double-blind Study to Investigate the Long Term Safety of Fezolinetant in Japanese Women Suffering From Vasomotor Symptoms (Hot Flashes) Associated With Menopause

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06206421
• Other study ID #: 2693-CL-0311
• Secondary ID: jRCT2031230584
• Status: Recruiting
• Phase: Phase 3
• Start date: February 22, 2024
• Est. completion date: April 30, 2026

Study information

• Verified date: June 2024
• Source: Astellas Pharma Inc
• Contact: Astellas Pharma Inc.
• Phone: +81-3-3244-6500 Japanese only
• Email: astellas.registration[@]astellas.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Hot flashes are the most common reason women going through menopause seek medical attention. Hormone replacement therapy, or HRT, is most often prescribed to treat hot flashes. However, HRT can't be used by all women or for as long as may be needed.

Researchers want to find other ways to treat hot flashes. Fezolinetant is a medicine to treat hot flashes in women going through menopause. Fezolinetant is an approved medicine in the US. Further studies are needed before it is available in other regions such as Asia.

In this study fezolinetant will be used to treat hot flashes in Japanese women going through menopause. This study will confirm the safety of fezolinetant and how well the women tolerate the treatment.

Women will either take fezolinetant or a placebo. This is decided by chance alone. The placebo looks like fezolinetant but will not have any medicine in it.

The women will take 1 tablet of the study medicine (fezolinetant or the placebo) once a day for up to 52 weeks.

During the study, the women will visit their study clinic for a check-up about every 4 weeks for up to 52 weeks (1 year). At each visit they will be asked if they had any medical problems. Other checks will include a medical examination and vital signs (temperature, blood pressure and pulse). At some visits, the women will have an ECG to check their heart rhythm and some blood and urine samples will be taken for laboratory tests. During a couple of visits, women who have a womb (uterus) will also have a test called a transvaginal ultrasound. A probe is gently placed inside the vagina. Sound waves will create a picture of the organs in the pelvis. This will allow the study doctor to look more closely at the uterus and surrounding organs.

The last clinic visit will be 3 weeks after the women take their final tablet of the study medicine (fezolinetant or the placebo).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 260
• Est. completion date: April 30, 2026
• Est. primary completion date: April 30, 2026
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 40 Years to 65 Years

Eligibility

Inclusion Criteria:

• Participant confirmed as menopausal per one of the following criteria at the screening visit (visit 1):

• For a post-menopausal participant: Spontaneous amenorrhea for >/=12 consecutive months; Spontaneous amenorrhea for >/=6 months with biochemical criteria of menopause (follicle-stimulating hormone (FSH) > 40 IU/L); Having had bilateral oophorectomy >/=6 weeks prior to the screening visit (visit 1) (with or without hysterectomy); Having had hysterectomy without bilateral oophorectomy with the biochemical criteria of menopause (FSH > 40 IU/L); or Having been confirmed to be post-menopausal in the 2693-CL-0310 study.

• For a peri-menopausal participant: Spontaneous amenorrhea for >/=60 days but < 6 consecutive months 2 times in the 2 most recent menstrual cycles with biochemical criteria of peri-menopause (FSH > 25 IU/L); or Spontaneous amenorrhea for >/=6 months but < 12 consecutive months with biochemical criteria of peri-menopause (FSH > 25 IU/L and = 40 IU/L); Having had hysterectomy without bilateral oophorectomy with the biochemical criteria of menopause (FSH > 25 IU/L and = 40 IU/L).

• Participant is seeking treatment for relief of vasomotor symptoms (VMS) associated with menopause.

• Female participant:

• Is not pregnant and at least 1 of the following conditions apply: Not a women of childbearing potential (WOCBP); WOCBP who has a negative urine pregnancy test day 1 (visit 2) and agrees to follow the contraceptive guidance from the time of informed consent through at least 21 days after final study intervention administration.

• Must not be breastfeeding or lactating starting at screening and throughout the investigational period and for 21 days after final study intervention administration.

• Must not donate ova starting at first administration of study intervention and throughout the investigational period and for 21 days after final study intervention administration

• Participant agrees not to participate in another interventional study while participating in the present study.

Exclusion Criteria:

• Participant has a history of an undiagnosed uterine bleeding within the 6 months prior to the screening visit (visit 1).

• Participant has a current malignant tumor or history (except for a participant who has not received treatment for malignant tumors for at least 5 years before informed consent acquisition and was not considered to have recurrence) of a malignant tumor except for non-metastatic basal cell carcinoma of the skin.

• Participant has a medical condition or chronic disease (including history of neurological [including cognitive], hepatic, renal, cardiovascular, gastrointestinal, pulmonary [e.g., moderate asthma], endocrine, or gynecological disease) that could confound interpretation of the study outcome.

• Participant uses a prohibited therapy (hormone therapy, hormone replacement therapy (HRT), hormonal contraceptive, any treatment for VMS [prescription medications, over-the-counter, or herbal/Kampo medicines] or strong or moderate cytochrome P450 1A2 (CYP1A2) inhibitors and is not willing to wash out or discontinue use of such drugs from screening visit (visit 1) through the follow-up visit (visit 16) or it is not medically appropriate to discontinue such drugs for the duration of the study.

• Participant has been randomized/registered in a clinical trial with fezolinetant previously or had previous exposure to marketed fezolinetant elsewhere.

• Participant has a present or previous history of participation in this study.

• Participant has received any investigational therapy within 28 days or 5 half-lives, whichever is longer, prior to screening visit (visit 1).

• Participant has an unacceptable result from the transvaginal ultrasound (TVU) assessment at screening (i.e., full length of endometrial cavity cannot be visualized or presence of clinically significant abnormal findings).

• Participant has documentation of a clinically significant abnormal Papanicolaou (Pap) test (or equivalent cervical cytology) within 52 weeks prior to the screening visit (visit 1) or at screening.

• Participant has active liver disease, jaundice, or elevated liver aminotransferases (alanine aminotransferase (ALT) or aspartate aminotransferase (AST)), elevated total bilirubin (TBL) or direct bilirubin (DBL), elevated international normalized ratio (INR), or elevated alkaline phosphatase (ALP) at screening. A participant with mildly elevated ALT or AST up to < 1.5 × upper limit of normal (ULN) can be enrolled if TBL and DBL are normal. Participant with mildly elevated ALP (up to < 1.5 × ULN) can be enrolled if cholestatic liver disease is excluded and no cause other than fatty liver is diagnosed. Participant with Gilbert's syndrome with elevated TBL may be enrolled as long as DBL, hemoglobin and reticulocytes are normal.

• Participant has creatinine > 1.5 × ULN or estimated glomerular filtration rate using the Modification of Diet in Renal Disease formula </=30 mL/min/1.73 m^2 at screening.

• Participant has positive hepatitis serology panel (i.e., positive hepatitis B surface (HBs) antigen and/or positive hepatitis C virus (HCV) antibody) at screening. If HCV antibody test result is equivocal, hepatitis C virus ribonucleic acid (HCV RNA) test at study site is allowed. Participant can be enrolled if that result is normal or not abnormal.

• Participant is not in good general health as determined on the basis of medical history and general physical examination performed at the screening; hematology parameters, biochemistry parameters, pulse rate, blood pressure, electrocardiogram (ECG) outside the reference range for the population studied, or is showing clinically relevant deviations.

• Participant has a history of suicide attempt or suicidal behavior within 52 weeks prior to study enrollment or suicidal ideation within 52 weeks prior to study enrollment (a response of "yes" to question 4 or 5 on the suicidal ideation portion of the Columbia Suicide Severity Rating Scale (C-SSRS)), or is at significant risk to commit suicide at day 1 (visit 2).

• Participant is unable or unwilling to complete the study procedures.

• Participant has any condition which makes the participant unsuitable for study participation.

• Participant has a known or suspected hypersensitivity to fezolinetant or any components of the formulation used.

• Participant is the investigator or a member of the study site staff.

• Participant is an employee of Astellas, the study-related contract research organizations (CROs) or site management organizations.

Related Conditions & MeSH terms

• Hot Flashes

Intervention

Drug:
• Fezolinetant
oral
• Placebo
oral

Locations

Country	Name	City	State
Japan	Marunouchi no Mori Ladies Clinic	Chiyoda-ku	Tokyo
Japan	Medical Corporation Asbo Tokyo Asbo Clinic	Chuo-ku	Tokyo
Japan	Mori Ladies Clinic	Fukuoka-shi	Fukuoka
Japan	Medical Corp.SEIKOUKAI New Medical Research System Clinic	Hachioji-shi	Tokyo
Japan	Juno Vesta Clinic hatta	Matsudo-shi	Chiba
Japan	Kichijyoji Ladies Clinic	Musashino-shi	Tokyo
Japan	Daido Clinic	Nagoya-shi	Aichi
Japan	Shimamura Memorial Hospital	Nerima-ku	Tokyo
Japan	Yukawa Women'S Clinic	Nishitokyo-shi	Tokyo
Japan	GyNet Medical Corporation Minamimorimachi Ladies' Clinic	Osaka-shi	Osaka
Japan	Rikako Ladies Clinic	Osaka-shi	Osaka
Japan	Shimizu Ladies Clinic	Sakai-shi	Osaka
Japan	Kotoni Ladies Clinic	Sapporo-shi	Hokkaido
Japan	NISHIKAWA Women's Health Clinic	Sapporo-shi	Hokkaido
Japan	Chieko Yukika Lady's Clinic	Sendai-shi	Miyagi
Japan	Shimodaira Ladies Clinic	Suginami-ku	Tokyo
Japan	jMOG Medical Corporation Tanabe Ladies' Clinic	Takatsuki-shi	Osaka
Japan	Medical Corporation Associa Tamacenter Ladies Clinic	Tama-Shi	Tokyo
Japan	Women's Clinic LUNA Yokohama Motomachi	Yokohama-shi	Kanagawa

Sponsors (1)

Lead Sponsor	Collaborator
Astellas Pharma Inc

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with Adverse Events (AEs)	An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.; An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. This includes events related to the comparator, if applicable, and events related to the (study) procedures.	Up to Week 55
Secondary	Change from baseline in endometrial thickness in post-menopausal participants	Endometrial thickness is a measure of how thick the lining of the uterus is. Endometrial thickness will be measured by transvaginal ultrasound (TVU).	Baseline and up to Week 52
Secondary	Number of participants with laboratory value abnormalities and/or AEs	Number of participants with potentially clinically significant laboratory values.	Up to Week 55
Secondary	Number of participants with vital sign abnormalities and/or AEs	Number of participants with potentially clinically significant vital sign values.	Up to Week 55
Secondary	Number of participants with electrocardiogram (ECG) abnormalities and/or AEs	Number of participants with potentially clinically significant ECG values.	Up to Week 52
Secondary	Pharmacokinetics (PK) of fezolinetant in plasma: Concentration	Concentration will be recorded from the PK plasma samples collected.	Up to Week 52
Secondary	Pharmacokinetics (PK) of metabolite ES259564 in plasma: Concentration	Concentration will be recorded from the PK plasma samples collected.	Up to Week 52